Apatinib Mesylate

Phase 3Small molecule

Apatinib Mesylate is one of 574 small molecule programs targeting Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

573

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Gastric AdenocarcinomaActive, not recruiting

OsteosarcomaActive, not recruiting

Adenoid Cystic CarcinomaActive, not recruiting

ChondrosarcomaActive, not recruiting

Liver CancerActive, not recruiting

MeningiomaActive, not recruiting

Bone SarcomaActive, not recruiting

Lung AdenocarcinomaActive, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Active, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Gastric AdenocarcinomaPhase 2

Active, not recruiting

OsteosarcomaPhase 2

Active, not recruiting

Adenoid Cystic CarcinomaPhase 2

Active, not recruiting

ChondrosarcomaPreclinical

Active, not recruiting

Liver CancerPhase 2

Active, not recruiting

MeningiomaPreclinical

Active, not recruiting

Bone SarcomaPhase 2

Active, not recruiting

Lung AdenocarcinomaPhase 1

Active, not recruiting

Showing 10 of 24 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Apatinib Mesylate

BBukwang Pharmaceutical

Phase 3

3 2

Trodelvy

Gilead

Preclinical

37 3

MS Contin

Merck & Co.

Preclinical

2 4

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 5

Paracetamol

GSK

Preclinical

1 6

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 7

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 8

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 9

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 10

Naltrexone/bupropion

Novo Nordisk

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

N/ARecruiting

Small Cell Lung Cancer

NCT06480864

Phase 3Recruiting

Efficacy and Safety

NCT04342910

Q4 2026

Phase 3Not yet recruiting

Ovarian Cancer

NCT06539091

Phase 3Not yet recruiting

Ovarian Cancer

NCT06188455

Phase 2Recruiting

Small Cell Lung Cancer

NCT06483282

Q1 2027

N/ARecruiting

Treatment

NCT05751733

Clinical

Trials by Indication[1]

Gastric Cancer14 trials

Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT05342389·68 enrolled

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

Unknown status·TThe First Affiliated Hospital of Xiamen University·Phase 1/2·NCT04572542·46 enrolled

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

Not yet recruiting·FFujian Medical University·Phase 2·NCT05524974·203 enrolled

Show 11 more trials

A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment

Completed·BBukwang Pharmaceutical·Phase 1·NCT02711969·6 enrolled

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

Unknown status·FFujian Cancer Hospital·N/A·NCT04174339·20 enrolled

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Completed·FFujian Medical University·Phase 2·NCT04195828·106 enrolled

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Unknown status·ZZhou Fuxiang·Phase 2·NCT04781686·35 enrolled

Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer

Unknown status·FFudan University·Phase 2·NCT05095636·102 enrolled

Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer

Unknown status·TThe First Affiliated Hospital of Bengbu Medical University·Phase 2·NCT03219593·30 enrolled

Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Not yet recruiting·FFujian Medical University·Phase 3·NCT07314203·118 enrolled

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Unknown status·RRemeGen Co., Ltd.·Phase 3·NCT04714190·351 enrolled

A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 4·NCT02776527·40 enrolled

Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens

Unknown status·FFujian Cancer Hospital·Phase 2·NCT04089657·40 enrolled

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Completed·FFujian Cancer Hospital·Phase 2·NCT05223088·40 enrolled

Hepatocellular Carcinoma5 trials

SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma

Unknown status·ZZhejiang University·Phase 2·NCT04930315·78 enrolled

A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin

Unknown status·—·Phase 2·NCT04850040·15 enrolled

Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma

Active, not recruiting·SShanghai Zhongshan Hospital·Phase 2/3·NCT04521153·294 enrolled

Show 2 more trials

A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·Phase 1/2·NCT02772029·30 enrolled

Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 3·NCT05613478·130 enrolled

Breast Cancer3 trials

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT06255392·200 enrolled

Breast Cancer Treatment Based on Organ-like Culture

Unknown status·XXijing Hospital··NCT03925233·300 enrolled

Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Recruiting·FFujian Cancer Hospital·Phase 1/2·NCT05019690·29 enrolled

Ovarian Cancer3 trials

Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer

Unknown status·ZZhongshan Hospital Xiamen University·Phase 2·NCT04590625·58 enrolled

Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer

Not yet recruiting·—·Phase 3·NCT06539091·51 enrolled

Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 3·NCT06188455·37 enrolled

Small Cell Lung Cancer3 trials

A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer

Recruiting·JJin Ying·Phase 2·NCT06483282·38 enrolled

Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT02995187·25 enrolled

Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer

Recruiting·YYunpeng Liu·N/A·NCT06480864·38 enrolled

31 more indications

Apatinib3 trials

A Food Effect Study of Apatinib Mesylate in Healthy Subjects

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04341090·42 enrolled

Effect of Itraconazole on the Pharmacokinetics of Apatinib

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT02836171·20 enrolled

Effect of Rifampicin on the Pharmacokinetics of Apatinib

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT02836821·20 enrolled

Nasopharyngeal Carcinoma3 trials

Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma

Unknown status·WWei Jiang·Phase 2·NCT03612219·240 enrolled

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Completed·WWei Jiang·Phase 2·NCT04350190·25 enrolled

Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma

Unknown status·—·Phase 2·NCT03130270·29 enrolled

Colorectal Cancer3 trials

Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)

Unknown status·SShenzhen People's Hospital·Phase 2·NCT03271255·80 enrolled

Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C)

Suspended·SShenzhen People's Hospital·N/A·NCT03743428·40 enrolled

Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer

Unknown status·ZZhongshan Hospital Xiamen University·Phase 1/2·NCT04202978·23 enrolled

Advanced Solid Tumor2 trials

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04457180·18 enrolled

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04322552·18 enrolled

First-line Treatment2 trials

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

Recruiting·TThe First Affiliated Hospital of Bengbu Medical University·Phase 2·NCT05192798·128 enrolled

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Completed·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT05156970·81 enrolled

Gastric Adenocarcinoma2 trials

PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma

Unknown status·—·Phase 2·NCT04006821·30 enrolled

Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma

Unknown status·HHenan Cancer Hospital·Phase 2·NCT04948125·20 enrolled

Osteosarcoma2 trials

Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma

Unknown status·PPeking University People's Hospital·Phase 2·NCT04351308·60 enrolled

Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma

Completed·PPeking University People's Hospital·N/A·NCT04690231·79 enrolled

Melanoma2 trials

PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT03955354·30 enrolled

Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT04397770·40 enrolled

Non-Small Cell Lung Cancer2 trials

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Unknown status·PPeking University Third Hospital·Phase 1·NCT03050411·30 enrolled

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04203485·762 enrolled

Preoperative1 trial

Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma （SPARE-02）

Completed·—·Phase 2·NCT05235100·30 enrolled

Chondrosarcoma1 trial

Apatinib for Inoperable Advanced Chondrosarcoma

Completed·PPeking University People's Hospital·N/A·NCT04260113·40 enrolled

Efficacy and Safety1 trial

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04342910·550 enrolled

Unknown status·—·Phase 2·NCT04204577·90 enrolled

Impaired Renal Function1 trial

A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04414852·24 enrolled

Camrelizumab1 trial

Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT04683198·69 enrolled

Esophageal Squamous Cell Cancer1 trial

Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment

Completed·YYuhong Li·Phase 2·NCT02976896·43 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma

Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT04440917·32 enrolled

Gastrointestinal1 trial

An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal

Unknown status·HHarbin Medical University·Phase 2·NCT05225844·150 enrolled

Metastatic Head and Neck Cancer1 trial

A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers

Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT03096184·38 enrolled

Squamous Cell Carcinoma1 trial

A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Completed·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT03267121·38 enrolled

Pancreatic Cancer1 trial

Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer

Not yet recruiting·ZZhejiang University·Phase 2·NCT06759090·43 enrolled

Rhabdomyosarcoma1 trial

Efficacy and Safety of Radiotherapy Combined With Apatinib Mesylate in the Treatment of Rhabdomyosarcoma in Children

Unknown status·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·Phase 1/2·NCT03868852·48 enrolled

Concurrent Chemoradiotherapy1 trial

Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD

Not yet recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT07357532·44 enrolled

Bone Sarcoma1 trial

Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study

Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT03539172·61 enrolled

Lung Adenocarcinoma1 trial

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR

Unknown status·—·Phase 1·NCT02691871·20 enrolled

Adenoid Cystic Carcinoma1 trial

A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck

Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT02775370·68 enrolled

Meningioma1 trial

Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults

Recruiting·—·N/A·NCT04501705·29 enrolled

Soft Tissue Sarcoma1 trial

Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04126811·120 enrolled

Treatment1 trial

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Recruiting·XXiangya Hospital of Central South University·N/A·NCT05751733·258 enrolled

Sources

References

[1]
ClinicalTrials.gov — 71 trial records for Apatinib Mesylate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Apatinib Mesylate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Apatinib Mesylate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bukwang Pharmaceutical company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBukwang Pharmaceutical

Apatinib Mesylate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Trials by Indication[1]

Gastric Cancer14 trials

Hepatocellular Carcinoma5 trials

Breast Cancer3 trials

Ovarian Cancer3 trials

Small Cell Lung Cancer3 trials

Apatinib3 trials

Nasopharyngeal Carcinoma3 trials

Colorectal Cancer3 trials

Advanced Solid Tumor2 trials

First-line Treatment2 trials

Gastric Adenocarcinoma2 trials

Osteosarcoma2 trials

Melanoma2 trials

Non-Small Cell Lung Cancer2 trials

Preoperative1 trial

Chondrosarcoma1 trial

Efficacy and Safety1 trial

Differentiated Thyroid Carcinoma1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Liver Cancer1 trial

Impaired Renal Function1 trial

Camrelizumab1 trial

Esophageal Squamous Cell Cancer1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Gastrointestinal1 trial

Metastatic Head and Neck Cancer1 trial

Squamous Cell Carcinoma1 trial

Pancreatic Cancer1 trial

Rhabdomyosarcoma1 trial

Concurrent Chemoradiotherapy1 trial

Bone Sarcoma1 trial

Lung Adenocarcinoma1 trial

Adenoid Cystic Carcinoma1 trial

Meningioma1 trial

Soft Tissue Sarcoma1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News